LC-PROM: Validation of a patient reported outcomes measure for liver cirrhosis patients by unknown
RESEARCH Open Access
LC-PROM: Validation of a patient reported
outcomes measure for liver cirrhosis patients
Ying Zhang, Yuanyuan Yang, Jing Lv and Yanbo Zhang*
Abstract
Background: The aim of the study is to develop a specific patient-reported scale of liver cirrhosis according to the
Patient Reported Outcome guidelines of the Food and Drug Administration (FDA), and to examine its capacity to
fill gaps in this field.
Methods: A conceptual framework was developed and a preliminary item pool developed through literature review
and interviews of 10 patients with liver cirrhosis. With the preliminary items, we performed a pilot survey that included
a cognitive test with patients and interviews with experts; the focus was on content and language of the scale. In the
item selection stage, seven statistical methods including discrete trends method, discrimination analysis, exploratory
factor analysis, Cronbach’s α coefficient, correlation coefficient, test-retest reliability, Item-Response Theory were applied
to survey data from 200 subjects (150 liver cirrhosis patients and 50 controls). This produced the preliminary Liver
Cirrhosis Patient-reported Outcome Measure (LC-PROM). In the next stage, we conducted the survey with 620 subjects
(500 patients and 120 controls) to validate reliability, validity and acceptability of this scale.
Results: The 55 items and 13 dimensions addressed four domains: physical, psychological, social, and therapeutic.
Cronbach’s α coefficients were 0.921 for the total scale; the confirmatory factor analysis, t-tests and ANOVA supported
scale validity; the model fit index as Root Mean Square Error of Approximation (RMSEA), Root Mean Square Residual
(RMR), Normed Fit Index (NFI), Non-Normed Fit Index (NNFI), Comparative Fit Index (CFI) and Incremental Fit Index (IFI)
met the criterion generally. The acceptance ratio and response rate indicated good feasibility.
Conclusions: This study developed an accurate and stable patient-reported outcome scale of liver cirrhosis, which is
able to evaluate clinical effects effectively, is helpful to patients in recognizing their health condition, and contributes to
clinical decision making both for patients and physicians. Additionally, the LC-PROM can perform as an ultimate
assessment of medical and health care effects and can inform clinical trials of new drugs for liver cirrhosis.
Keywords: Liver cirrhosis, Patient-reported outcome (PRO), Item selection, Item Response Theory (IRT), Confirmatory
factor analysis (CFA), Reliability, Validity
Background
Liver cirrhosis (LC) is a potential consequence of the
progression of any of various kinds of liver disease, and
the high incidence of hepatitis will lead to a large number of
patients suffering from liver cirrhosis. LC is characterized by
fatigue, digestive disorders, bleeding and anemia, endocrine
disorder, hypoproteinemia, portal hypertension and other
serious symptoms that cause great pain to patients physically,
impacting their daily social life. As an irreversible, chronic,
progressive disease. LC can not be cured completely at the
present stage. Particularly for weak patients, the common
treatments used in the clinical can cause secondary damage
in addition to harm caused by the disease itself.
At present, patients’ health status and treatment effects
are evaluated by hepatic function test and serological
markers, or reflected by hospital stays and symptom im-
provement over time. However, with the continued devel-
opment of a biopsychosocial medical model the use of
scales to assess patients’ fitness has been widely accepted
and applied internationally; that is, patients’ personally
reported data, dubbed patient-reported outcome (PRO),
are used to measure clinical results. One of the arguments
for using questionnaires to ask patients to judge their own
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health-related quality of life (HRQoL) is that it has been
shown that physicians are generally unable to make ac-
curate judgments of patients’ HRQoL. Physicians’ judgments
not only deviate from those of patients, they also differ
among one another. This latter variability makes it particu-
larly difficult to obtain ‘objective’ judgments of HRQoL [1].
The PRO Harmonization Group, which consists of the
Food and Drug Administration (FDA), International Society
For Pharmacoeconomics and Outcomes Research (ISPOR),
the European Regulatory Issues on Quality of Life Assessment
Group (ERIQA), and the International Society for Quality of
Life Studies (ISQOL), proposes that evaluation of clinical cura-
tive effects should contain data from physicians’ reports,
physiological measures, caregivers’ reports, and PROs, which
come solely from the patient. In the course of a disease, there
are some symptoms that can only be experienced by patients;
i.e., these symptoms cannot be reflected by physical measures.
In this case, the normal reference values of medicine do not
equal true health; additionally, physician report data are always
processed through the subjective consciousness and may only
include contents related to the physician’s concerns. What’s
more, this report is limited by physicians’ knowledge and ex-
perience. Therefore, PROs play an important role in clinical
practice, and this method is now generally accepted by experts
and patients alike. Since the publication of the draft guide for
new drug development and curative effect evaluation in
February 2006 [2], PROs are becoming more important in as-
sessment of treatment outcome and in new drug registration.
A PRO instrument specific to LC could provide several bene-
fits: it could help improve the evidence base through research
assessing effectiveness of LC therapies; facilitate clinician-patient
communication and shared decision making; help prioritize pa-
tient problems and preferences; monitor changes or outcomes
of treatment; measure the performance of healthcare providers
and services; and be incorporated in clinical audits [3–5].
In short, the aim of this study is to develop such a
PRO scale that meets the following criteria: (I) specific
to liver cirrhosis; (II) addresses all physical symptoms,
psychological feelings, daily activities, and therapeutic sta-
tus related to LC; (III) comprises items that are founded
on the patients’ own perspective; (IV) has good internal
consistency, a reasonable theoretical framework and can
distinguish different severities of the disease; and (V) is of
appropriate length and has strong feasibility.
Methods
The Medical Ethics Committee of Shanxi Medical Univer-
sity provided ethics approval, and all participants signed
informed consent to participate.
Step 1 item generation
Literature review
We conducted literature searches on databases and net-
work resources for PRO instruments. From the searches,
we formed the conceptual framework of the new instru-
ment, called the Liver Cirrhosis Patient Reported Outcome
Measure (LC-PROM).
Patient interviews
We conducted semi-structured interviews with ten liver
cirrhosis patients (five males and five females; average
age 53 years). In the interview, patients were encouraged
to talk about their main disease symptoms, physical feel-
ings and symptoms that they most desired to improve,
psychological conditions after diagnosis and participation
in social activities since diagnosis, adherence to therapy
and satisfaction with their status. In addition, patients
could speak freely on other relevant topics. Throughout
the process, researchers wrote down the interviewees’ ori-
ginal words as far as possible, and audio recordings were
made. After the interview, all information was sorted and
then an initial list of items was developed.
Cognitive debriefing and discussion with experts
Another ten patients (five males and five females, average
age 52 years) were selected to undertake cognitive debrief-
ing. These patients were asked to flag items that were am-
biguously worded or difficult to understand, and to suggest
items that needed to be added or deleted.
Seven experienced experts including three chief physi-
cians of gastroenterology, one infectious diseases phys-
ician, one psychologist, one sociologist, and one ethics
expert were invited to discuss whether the initial structural
framework was reasonable and whether the items covered
all areas of disease evaluation. The correlation of items
with their respective dimensions and linguistic issues were
considered. We modified the item pool according to the
experts’ advice, and the preliminary scales were formed.
Step 2 item selection
Sampling survey
Two hundred subjects were sampled from inpatients of
eight different hospitals and communities in Shanxi Prov-
ince. There were 150 LC patients and 50 health controls.
Patients who were diagnosed with definite LC, who
were between 18 and 72 years old, and who were fully
able and willing to participate in this study as volunteers
were included.
Patients were excluded if they had an uncertain diag-
nosis, suffered mental illness or disorders of conscious-
ness, were unable to understand questions because of
dysgnosia, or were unable to complete the test.
Health controls were healthy volunteers from commu-
nities who were not diagnosed with any diseases by phy-
sicians and had an age distribution similar to that of LC
patients. Health controls also provided informed consent
and got some rewards.
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The survey was administered by trained investigators.
Before beginning, subjects were informed of the survey
objective and signed the informed consent form. Next,
the participants independently completed the prelimin-
ary scale. During the survey, investigators were present
to respond to questions. If participants were elderly or
had a low education level, investigators read the items to
them and wrote down their answers. After the survey,
any incomplete scales were filled in by the subjects under
the guidance of the investigators.
Scale scoring
Scores were calculated using a five-point Likert scale to
reflect frequency of occurrence over the past 2 weeks of
the issue presented in each item. The responses were 0 =
never, 1 = occasionally, 2 = about half of the time, 3 =
often, and 4 = almost every day. The positively-toned items
were scored as the original score plus one, and the
negatively-toned items were scored as 5 minus the original
score. Thus every item score ranged from 1 to 5, with
higher scores denoting more positive outcomes.
Statistical methods for item selection
Item reduction was based on both Classical Test Theory
(CTT) and Item Response Theory (IRT). This study
employed six methods of CTT followed by IRT.
Discrete trend
A low discrete degree means subjects were inclined to
select the same answer; that is, the items had a low cap-
acity to test for differences. In general, scores obey a
normal distribution, so the standard deviation for every
item was calculated. The items with a low standard devi-
ation (<1.0) were deleted.
Discrimination analysis
Items that do not reflect different characteristics of sub-
jects should not remain in the scale. We compared every
item score with two independent-sample t-tests (α = 0.05),
and the items that were not statistically different were
deleted.
Exploratory factor analysis (EFA)
Taking the small sample size into consideration, we did
EFA in each domain (physical, psychological, social, and
therapeutic) separately, then rotated the solution. Ac-
cording to the eigenvalue and the variance contribution
ratio, the number of factors was determined. Items with
low factor loading (<0.4) and cross-loading on two or
more dimensions were removed.
Cronbach’s α if item deleted (CAID)
Internal consistency was evaluated with CAID and the
Corrected Item Total Correlation (CITC). If the α
coefficient increased greatly when an item was deleted, the
item was reducing the internal consistency of its own di-
mension. CITC < 0.4 indicates an item poorly contribut-
ing to the construct of the scale; therefore such items
were deleted.
Correlation coefficient
The representativeness of an item was measured by its
correlation coefficient with the dimension to which the
item belonged. When the value was less than 0.6, the
item was not retained.
Retest reliability
This method considered item stability. Thirty subjects
were selected from the sample to take a retest 2 weeks
after the first test. Among these, 20 cases whose data
were error-free in both tests were used to calculate retest
correlation coefficient. The criterion for reliability was 0.7.
Item response theory (IRT)
IRT is part of modern measurement theory and was put
forward to overcome defects of CTT [6]. It is also called
latent trait theory, and has advantages for item selection
and test construction. It claims that there is a functional
relationship between subjects’ abilities and their responses
to an item. How to define this relationship is the basic
idea and the starting point. In brief, IRT can be viewed as
a probabilistic method for discussing the relationship
between subjects’ potential traits and their responses to
items.
If θ represents a subject’s ability, P(θ) is the probability
of the subject’s responding to an item correctly; their
functional relationship can be reflected by a curve called
the item characteristic curve (ICC). Two important pa-
rameters on the curve are used in this study: a reflects
discriminant degree and b shows item difficulty. On the
ICC whose X,Y axes are θ and P(θ), b is the value of θ
corresponding to P(θ) = 0.50; this value ranges from −3
to 3. a is the function of the tangent line’s slope at point
b; its value ranges between 0.3 and 2, with larger values
representing higher degrees of discrimination.
Because the five-point Likert scale was being used, a
Graded Response model was constructed, which is ap-
propriate for hierarchical and continuous data, extend-
ing a unidimensional model to a multidimensional one
[7]. The basic idea of the model [8] is that: assuming the
full score of an item is fj, then the number of scores for
item j is fj + 1, that is 0,1,2…,fj. If Pajt* is the probability
that the score of item j is greater than t when the ability
value is θa, then Paj0* = 1, Paj, fj+1* = 0. If Pajt is also the
probability that the score of item j is t [9], then Pajt =
Pajt*-Paj, t+1* (t = 0,1,2, …, fj), where Pajt* = 1/{1 +
exp[−Daj(θa-bjt)]}, in which D = 1.7, aj is the discrimin-
ant degree of item j, bjt is the difficulty when the score
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of item j is t, and the difficulty level of item j is mono-
tonically increasing; that is, bj1 < bj2 <… < bj,fj. Pajt* cor-
responding to an ICC is called the Project type
characteristic function in the Graded Response model.
Five parameters can be estimated in our study, namely
a,b1,b2,b3,b4, where b1 is the parameter of difficulty
level between answer 1 and answer 2, and so on, and
b1<b2<b3<b4. Here a must be > 0.60, and b ranges
from −3 to 3.
Items supported by at least five methods were retained
in the final LC-PROM.
Step 3 validation of the scale
Second Sampling Survey
Six hundred twenty subjects were selected in the second
survey, of which 120 were controls. Inclusion and exclu-
sion criteria did not change, nor did the survey process.
Reliability analysis
Reliability reflects the stability and consistency of a scale.
In our study, Cronbach’s α coefficients for the total scale
and for each domain were calculated, to evaluate the aver-
age consistency of the items. The higher the value is, the
better the reliability, but if α is too high, it suggests that the
items are not simply related but overlap considerably. In
the extreme case where α = 1,we should consider whether
some items are redundant and could be eliminated. Here
we chose 0.80 as the critical value; i.t., the measured results
can be considered stable when α exceeds 0.80.
Validity analysis
Validity, also called accuracy, is the other arm of validation
of a scale, and reflects the extent to which a scale measures
what it sets out to measure. Validity includes subtypes
of content validity, criterion validity, construct validity,
and discriminant validity. In this article, we chose to
measure the latter two.
Construct validity
This index shows whether the scale constructs match
those in the initial framework. A scale with good con-
struct validity is able to target true potential traits for
measurement. Factor analysis is a major method for con-
struct validity analysis and includes Exploratory Factor
Analysis (EFA) and Confirmatory Factor Analysis (CFA).
When an item collection is not based on theoretical
guidance, EFA has the ability to explore the fields and
dimensions belonging to a scale. However, before this
study, we had reviewed the literature to formulate a
scale framework, and EFA had been applied during the
process of item selection, so at this stage CFA was suit-
able. Factor loading for every item and fit index for every
domain were calculated.
Discriminant validity
This is an index of a scale’s ability to discriminate popula-
tions with different traits through comparing test results
of selected subjects. The statistical method was a simple
two-independent samples t-test. The total scores on the
LC-PROM and on each domain were compared between
cases and controls to judge whether the LC-PROM could
distinguish these two groups. In addition, we stratified the
time that patients had been sick as less than 1 year, 1 to
3 years, 3 to 5 years, and more than 5 years. ANOVA was
then applied to infer the relationship between disease
course and scale score. The scale we developed had a good
discriminant validity when p ≤ 0.05.
Feasibility analysis
When a scale can be understood and completed by sub-
jects easily, the scale is said to have strong feasibility.
This property is assessed with reference to acceptance
ratio, response rate, and completion time.
Statistical software
The data analysis was conducted by SPSS16.0, Multilog7.03
and LISREL8.70.
The entire study flow diagram is presented in Fig. 1.
Results
Generation of item pool
Literature review and patient interviews
Database searches revealed some liver disease-specific
scales, such as the Hepatitis Quality Of Life Questionnaire
(HQLQ) [10, 11], the Liver Disease Quality Of Life
(LDQOL) [10, 11], the Chronic Liver Disease Question-
naire (CLDQ) [10–13], and several related questionnaires
such as the WHOQOL-BREF [11], the SF-36 [10, 11], the
SCL-90 [12, 13] and the Hospital Anxiety and Depression
Scale (HADS) [12, 13].
The LC-PROM focused on 4 domains: Physical (PHD),
Psychological (PSD), Social (SOD), and Therapeutic (TRD).
This idea is based on the definition of PRO and all the
specific scales for liver disease. Meanwhile, taking the
Social Avoidance and Distress Scale (SAD) and the
Beck Hopelessness Scale (BHS) into consideration, the
LC-PROM was divided into a further 13 dimensions,
and the initial item pool included 72 items (see
Appendix 1). The instrument’s conceptual framework
is shown in Table 1.
Cognitive debriefing and expert discussion
The LC-PROM was regarded as clear and concise, easy
to understand and easy for the patients in the cognitive
debriefing to complete. Completion time was 10 min on
average. Considering patients’ suggestions, we made
some modifications to the instrument. Six items in PHD
Zhang et al. Health and Quality of Life Outcomes  (2016) 14:75 Page 4 of 16
that described atypical symptoms and overlapped with
each other were deleted. Symptoms in deleted items in-
cluded, for example, oliguria, dry eyes, pale skin and
mucosa, among others. We also replaced the words
“hepatic region” with “right upper abdomen,” to make
this text easier to understand. Similarly, two items were
reduced in PSD, one item was reduced in TRD, and
one item was added in SOD.
Experts agreed that the LC-PROM was reasonable in
its construction framework and item attributions, and
that it was comprehensive in its content. However, be-
cause this was a self-rating scale, it was determined
that the items should be expressed in the first person, so a
full revision was made by research group accordingly. This
second draft of the preliminary LC-PROM included 64
items, 13 dimensions and four fields (see Appendix 2).
Item reduction
Participant characteristics
We sampled 200 participants in this survey; 189 responded,
for an acceptance rate of 94.50 %. There were 179 subjects,
including 132 patients and 47 controls, whose data were
available, for a final response rate of 94.71 %. Baseline data of
participants are shown in Table 2. The average length of time
since liver cirrhosis diagnosis was approximately 3.02 years.
Item selection based on CTT and IRT
When CAID was used, we calculated the initial Cron-
bach’s α coefficient when all 64 items were retained; this
did not result in deletion of any items, the detailed result
was not shown here.
In IRT a number of items were suggested for deletion:
fourteen in PHD, four in PSD, and seven in TRD; and
only one item was retained in SOD according to param-
eters a and b. Fig. 2 shows the ICC matrix.
Fig. 1 Study flow diagram
Table 1 Preconceived conceptual framework for the LC-PROM
Field Dimension





Psychological Domain (PSD) Anxiety and Depression (AND)
Confidence (CON)
Disease Outcomes (DIO)
Social Domain (SOD) Social Supports (SOS)
Social Adaptation (SOA)
Therapeutic Domain (TRD) Satisfaction (SAT)
Compliance (COM)
Drug Side Effects (DSE)
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Fifteen items were to be deleted based on statis-
tical results, but considering the value of disease-
specific symptom information and the contributions
of certain items to each dimension, six items were
maintained in the final version of the LC-PROM.
The final version comprised 55 items within 13 di-
mensions belonging to 4 domains (see Appendix 2).
The detailed screening process is presented in
Table 3, and the final construction frame can be seen
in Table 4.
Table 2 Baseline data for participants in pilot survey
Variables Liver Cirrhosis Health Control t/χ2 P




Height (cm) 167.46 ± 7.68 166.04 ± 7.53 1.091 0.277
Weight (kg) 62.83 ± 10.42 65.83 ± 12.79 −1.596 0.112









Fig. 2 Matrix plot of item characteristic curve
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Table 3 Item selection outcome based on CTT and IRT
Dimension Item SD t Factor
Loading
CAID CITC CC Retest
Reliability
IRT Outcome
a b1 b2 b3 b4
ABS PHD1 1.18 0.001 0.619 0.736 0.579 0.713 0.858 1.83 −1.07 −0.02 0.91 2.20 √
PHD2 0.90 0.001 0.474a 0.774 0.348 0.484 0.860 1.06 −6.98 −2.53 −0.43 1.41 ×
PHD3 1.21 0.001 0.540a 0.750 0.509 0.659 0.734 1.17 −1.80 −0.34 0.86 2.20 √
PHD4 1.25 0.001 0.671 0.756 0.478 0.639 0.802 1.37 −1.60 −0.31 0.76 1.79 √
PHD5 0.97 0.001 0.697 0.752 0.505 0.628 0.817 1.15 −3.16 −2.50 −1.06 0.70 √
PHD6 1.21 0.001 0.510a 0.771 0.392 0.566 0.644 0.91 −2.58 −0.74 0.58 2.38 ×
PHD7 1.20 0.001 0.620 0.747 0.525 0.670 0.886 1.47 −1.99 −0.97 0.07 1.24 √
PHD8 1.05 0.001 0.633 0.749 0.517 0.647 0.840 1.09 −2.81 −1.51 0.04 2.17 √
SKS PHD9 1.13 0.001 0.673 0.529 0.382 0.706 0.779 0.59 −5.48 −1.91 0.18 2.77 √
PHD10 1.01 0.001 0.668 0.473 0.421 0.644 0.751 0.61 −6.19 −3.45 −1.21 1.76 √
PHD11 1.12 0.001 0.543a 0.483 0.411 0.451 0.649 1.07 −3.40 −1.09 0.18 1.74 ×
APS PHD12 1.09 0.001 0.603a 0.519 0.535 0.718 0.732 1.21 −3.04 −1.85 −0.43 0.77 √
PHD13 1.21 0.001 0.655a 0.612 0.307 0.574 0.719 1.20 −1.81 −0.36 0.75 2.16 ×
PHD14 1.23 0.001 0.642 0.618 0.295 0.567 0.713 0.75 −3.40 −1.55 0.06 1.89 ×
PHD15 1.03 0.001 0.672 0.584 0.376 0.589 0.767 0.92 −4.20 −2.45 −1.09 0.82 ×
PHD16 0.89 0.915 0.528a 0.590 0.367 0.555 0.809 0.80 −5.28 −4.08 −2.12 −0.43 ×
PHD17 1.14 0.001 0.698 0.600 0.400 0.576 0.781 0.57 −4.35 −1.35 0.81 3.86 √
COG PHD18 1.20 0.001 0.816 0.438 0.567 0.831 0.692 1.15 −2.22 −0.93 0.13 1.82 √
PHD19 1.14 0.001 0.848 0.419 0.585 0.829 0.727 0.87 −3.59 −1.33 0.28 2.03 √
PHD20 1.12 0.001 0.584a 0.779 0.302 0.657 0.840 0.87 −2.74 −0.94 0.68 3.15 ×
IND PHD21 1.07 0.033 0.633 0.635 0.525 0.788 0.815 1.05 −3.25 −2.23 −0.80 0.81 √
PHD22 1.14 0.002 0.708 0.582 0.566 0.824 0.813 1.18 −2.92 −1.67 −0.40 0.82 √
PHD23 1.07 0.018 0.777 0.653 0.509 0.780 0.820 0.64 −5.93 −2.96 −0.93 1.40 √
AND PSD1 1.19 0.001 0.504a 0.807 0.532 0.645 0.774 1.54 −1.26 −0.26 0.77 2.33 √
PSD2 1.07 0.001 0.704 0.805 0.558 0.656 0.768 1.33 −2.85 −1.11 0.33 1.62 √
PSD3 1.39 0.001 0.606 0.814 0.481 0.622 0.628 0.97 −1.96 −0.61 0.61 1.41 √
PSD4 1.21 0.001 0.680 0.797 0.624 0.721 0.829 2.16 −0.91 0.09 0.95 1.86 √
PSD5 1.19 0.001 0.611 0.809 0.517 0.633 0.814 1.04 −2.64 −0.97 0.17 1.85 √
PSD6 1.36 0.001 0.699 0.804 0.555 0.679 0.781 1.19 −1.24 −0.23 0.64 1.96 √
PSD7 1.20 0.001 0.658 0.809 0.513 0.631 0.817 1.17 −2.78 −1.24 −0.20 0.99 √
PSD8 1.36 0.001 0.589 0.809 0.516 0.648 0.626 1.17 −1.74 −0.51 0.34 1.44 √
PSD9 1.16 0.001 0.597a 0.813 0.476 0.596 0.858 1.45 −2.31 −0.34 0.42 1.74 √
CON PSD10 1.34 0.001 0.691 0.624 0.237 0.511 0.830 0.78 −1.59 0.05 1.45 2.85 √
PSD11 0.94 0.001 0.623a 0.590 0.328 0.509 0.844 0.68 −5.55 −4.47 −2.09 0.33 ×
PSD12 1.43 0.001 0.650 0.611 0.283 0.564 0.722 0.60 −2.71 1.20 0.21 1.95 √
PSD13 0.93 0.001 0.676 0.591 0.326 0.505 0.860 0.61 −7.67 −4.43 −1.99 0.69 ×
PSD14 1.02 0.001 0.632 0.546 0.471 0.640 0.804 1.24 −4.19 −1.87 −0.43 0.85 √
PSD15 1.03 0.001 0.634 0.551 0.454 0.629 0.776 0.85 −4.51 −2.66 −1.29 0.70 √
PSD16 1.25 0.001 0.504a 0.587 0.334 0.571 0.721 0.95 −2.97 −1.23 −0.20 1.19 ×
DIO PSD17 1.16 0.001 0.749 - 0.461 0.836 0.736 1.20 −2.17 −0.65 0.66 2.05 √
PSD18 1.31 0.001 0.686 - 0.461 0.873 0.782 1.25 −1.40 −0.23 0.82 1.85 √
SOS SOD1 0.85 0.836 0.719 0.476 0.480 0.702 0.854 1.23 −6.39 −2.98 −1.00 0.55 ×
SOD2 0.95 0.492 0.606a 0.567 0.336 0.628 0.842 0.89 −7.79 −2.62 −1.43 0.58 ×
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Validation of LC-PROM
Demographic characteristics
Another 620 subjects (500 cases and 120 controls) were
sampled for the validation. Of the 598 who responded,
576 produced valid data for analysis (464 cases and
112 controls). Participant characteristics are presented
in Table 5.
As Table 5 shows, males were more numerous than fe-
males; subjects’ average age was 50–55 years. There were
no statistically significant differences in the distributions
of gender, age, or height between the two groups. LC pa-
tients had a higher proportion of smoking and drinking,
and lower weight. These characteristics are consistent with
risk factors for LC. Among the subjects, 269 patients had
been sick for 1 to 5 years, the number of patients who
suffered from LC less than 1 year and more than 5 years
were 97 and 98 respectively, the average length of time
was 3.70 years.
Reliability analysis
Cronbach’s α coefficient is one of the indicators for
evaluating reliability, with a generally acceptable value of
greater than 0.70. Our LC-PROM met this standard, ex-
cept in the TRD domain (see Table 6).
Table 3 Item selection outcome based on CTT and IRT (Continued)
SOD3 0.90 0.480 0.767 0.462 0.489 0.720 0.855 0.60 −6.92 −5.35 −2.33 0.36 ×
SOD4 1.26 0.036 0.579a 0.636 0.296 0.690 0.785 0.94 −2.47 −0.44 0.73 2.05 √
SOA SOD5 1.06 0.001 0.786 0.797 0.543 0.646 0.731 0.44 −6.55 −4.41 −1.26 2.72 √
SOD6 1.27 0.001 0.835 0.792 0.576 0.692 0.741 0.25 −8.24 −4.67 −0.42 4.89 √
SOD7 1.22 0.001 0.438a 0.804 0.481 0.611 0.771 0.38 −5.95 −2.52 0.75 3.99 √
SOD8 1.26 0.001 0.385 0.803 0.488 0.621 0.849 0.57 −3.06 −0.25 1.91 3.49 √
SOD9 1.26 0.001 0.821 0.809 0.433 0.566 0.742 0.46 −6.51 −2.60 −0.23 2.69 √
SOD10 1.19 0.001 0.630 0.793 0.575 0.685 0.638 0.79 −3.19 −1.53 0.32 2.02 √
SOD11 1.18 0.017 0.693 0.803 0.490 0.614 0.757 0.67 −4.33 −1.78 −0.01 2.18 √
SOD12 1.28 0.015 0.748 0.799 0.525 0.653 0.915 0.49 −4.45 −1.79 0.52 2.82 √
SOD13 1.17 0.001 0.713 0.796 0.545 0.659 0.832 0.41 −5.81 −2.58 0.77 4.31 √
SAT TRD1 1.03 0.001 0.755 0.505 0.434 0.752 0.739 0.88 −4.05 −1.27 0.92 2.53 √
TRD2 0.98 0.009 0.722 0.498 0.441 0.742 0.759 0.58 −7.28 −2.96 0.05 3.16 √
TRD3 1.13 0.001 0.720 0.552 0.406 0.765 0.878 0.46 −4.13 −0.88 2.86 5.24 √
COM TRD4 1.03 0.537 0.794 0.524 0.449 0.767 0.825 0.42 −8.59 −5.10 −2.36 1.43 √
TRD5 1.11 0.039 0.617 0.587 0.413 0.771 0.728 0.61 −6.83 −2.68 −1.25 1.19 √
TRD6 0.89 0.043 0.778 0.499 0.479 0.747 0.834 0.49 −9.49 −5.76 −3.07 0.59 √
DSE TRD7 1.23 0.001 0.801 0.444 0.494 0.744 0.716 1.06 −2.04 −0.57 0.80 2.10 √
TRD8 1.26 0.001 0.683 0.504 0.417 0.701 0.632 0.61 −3.48 −0.34 1.12 3.19 √
TRD9 1.23 0.005 0.487a 0.564 0.338 0.640 0.669 0.95 −2.00 −0.86 0.77 2.42 ×
TRD10 1.28 0.006 0.631 0.602 0.290 0.618 0.702 0.82 −1.93 −0.03 1.32 2.66 √
Note: “CC” is short of correlation coefficient, boldface means items which suggested to delete by certain method, “a” means items that measure cross dimensions,
“√”means maintain, “×”means delete







Skin Symptom (SKS) 7-,8-
Appetite Symptoms (APS) 9-,10-,11-,12-,13-








Disease Outcomes (DIO) 15-,16-
Social Domain
(SOD)
Social Supports (SOS) 1+,2+,3+





Drug Side Effects (DSE) 7-,8-,9-
Note: “+”means positive item, “-”means negative item
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Validity analysis
a. Construct validity: Results of CFA are listed in Tables 7
and 8, and show factor loadings of items and goodness
of fit of domains in the final LC-PROM.
As the tables show, standard factor loadings of each
item were above 0.50, except for SOD3; therefore, the
goodness of fit for LC-PROM is satisfactory.
b. Discriminant validity: Discriminant validity analysis
was conducted by comparing average scores across
different domains as well as total scale scores between
patients with various disease courses and the health
controls.
In Table 9, the scores of patients are lower than those
of controls, suggesting that LC severely affected patients’
quality of life. With SOD as the exception, scores were
significantly different, as seen in Table 10, and longer
clinical courses were associated with lower scores. Perhaps
because LC is the final stage of liver disease progression,
by the time patients have received a definite diagnosis,
they may already have lost the ability to engage in social
activity; therefore scores in this domain did not differ. Of
course, measurement error cannot be excluded as an ex-
planation, but it had little effect on discriminant validity.
In summary, the LC-PROM was well able to differentiate
health and LC patients in varying clinical courses.
Feasibility analysis
The acceptance rate and response rate for the LC-PROM
tool were 96.45 % and 92.32 %, respectively. Its average
completion time was 10 min.
Discussion
LC is a chronic disease characterized by progressive liver
injury which imposes a heavy burden on medical and
health services. Bajaj J. S. etal revealed that patients had
significant impairment on all domains apart from anger
and anxiety compared with caregivers and US norms.
Decompensated patients had significantly worse sleep,
pain, social and physical function scores compared with
compensated ones [14]. Therefore, objective evaluation
of clinical effects and patients health conditions is critic-
ally important.
We performed reviews of the literature, then collected
symptoms of greatest concern and with greatest likeli-
hood of improvement, along with psychological condi-
tions and life states from the patients’ perspective. From
these, we formed the preliminary item pool for the LC-
PROM instrument. Cognitive debriefing and discussions
with experts were employed to ensure reasonableness of
the conceptual and the structural framework. Next we
applied this scale to two samples (n1 = 120, n2 = 620) that
represented different populations. We considered seven
statistical methods and clinical relevance when selecting
final items for this tool. In current study, the final ver-
sion of the LC-PROM comprised 55 items in 4 domains
(18 items in PHD, 16 items in PSD, 12 items in SOD, 9
items in TRD) that represent 13 dimensions. Validation
Table 5 Demographic characteristics of 464 patients and 112 controls in LC-PROM validation
Variables Liver Cirrhosis Health Control t/χ
2 P
Age (Years) 55.62 ± 11.06 53.81 ± 11.38 1.547 0.123
Gender Male 283 64 0.558 0.455
Female 181 48
Height (cm) 166.96 ± 7.76 167.73 ± 6.98 −0.967 0.334
Weight (kg) 62.08 ± 10.34 66.66 ± 9.95 −4.241 0.001









Table 6 Cronbach’s α coefficient of four domains and total
scale
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Table 7 Maximum Likelihood Estimation of CFA for LC-PROM
Domain Dimension Item Standard Factor Loading Nonstandard Factor Loading SE t
PHD ABS PHD1 0.81 0.95 0.04 22.79
PHD2 0.86 0.99 0.04 25.34
PHD3 0.83 0.99 0.04 23.77
PHD4 0.75 0.63 0.03 20.54
PHD5 0.63 0.61 0.04 16.19
PHD6 0.74 0.79 0.04 20.18
SKS PHD7 0.91 0.97 0.04 23.98
PHD8 0.76 0.78 0.04 19.59
APS PHD9 0.51 0.50 0.04 12.06
PHD10 0.63 0.63 0.04 15.66
PHD11 0.69 0.77 0.04 17.52
PHD12 0.71 0.72 0.04 18.17
PHD13 0.65 0.65 0.04 16.17
COG PHD14 0.89 0.89 0.03 25.82
PHD15 0.93 0.91 0.03 27.43
IND PHD16 0.76 0.69 0.04 19.38
PHD17 0.61 0.60 0.04 14.70
PHD18 0.82 0.75 0.04 21.13
PSD AND PSD1 0.83 0.95 0.04 23.99
PSD2 0.65 0.69 0.04 17.07
PSD3 0.89 1.04 0.04 27.23
PSD4 0.80 0.91 0.04 22.71
PSD5 0.69 0.72 0.04 18.65
PSD6 0.76 0.87 0.04 21.22
PSD7 0.66 0.72 0.04 17.59
PSD8 0.67 0.72 0.04 17.92
PSD9 0.83 0.95 0.04 23.91
CON PSD10 0.80 0.93 0.04 22.46
PSD11 0.87 0.95 0.04 25.62
PSD12 0.61 0.52 0.03 15.39
PSD13 0.59 0.51 0.03 14.82
PSD14 0.86 0.99 0.04 24.79
DIO PSD15 0.80 0.95 0.05 19.76
PSD16 0.83 0.99 0.05 20.54
SOD SOS SOD1 0.62 0.51 0.06 8.42
SOD2 0.59 0.49 0.06 8.31
SOD3 0.35 0.37 0.06 6.26
SOA SOD4 0.57 0.59 0.04 14.39
SOD5 0.86 0.96 0.04 24.93
SOD6 0.66 0.77 0.05 17.14
SOD7 0.70 0.91 0.05 18.57
SOD8 0.52 0.51 0.04 12.67
SOD9 0.72 0.80 0.04 19.26
SOD10 0.72 0.73 0.04 19.40
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of reliability, validity, and feasibility indicated that the
LC-PROM was accurate, reliable and easy to use, show-
ing great potential for clinical application.
Through our literature search, we confirmed that the
LC-PROM instrument is the first specific scale for LC.
The existing PROs for liver diseases are adapted from
quality of life measurement scales that are classified as a
universal QOL scale and a specific HRQOL scale. For
example, WHO Quality of Life-BREF(WHOQOL-BREF),
Short Form 36 (SF-36), Nottingham Health Profile
(NHP),and the sickness impact profile(SIP) are universal
scales, and the Chronic Liver Disease Questionnaire
(CLDQ), Hepatitis Quality Of Life Questionnaire (HQLQ),
and Liver Disease Quality Of Life (LDQOL) are specific
HRQOL scales. All the scales mentioned above have dif-
ferent degrees of defects and in any case do not apply to
LC patients. Some studies have indicated that the WHO-
QOL is widely used by researchers to study QOL of liver
transplant recipients, while the NHP focuses on more se-
vere levels of disability and has thus has been known to be
less sensitive to changes in conditions where effects are
relatively mild [15, 16]. The SIP, in contrast, has a broad
coverage of topics, but is therefore very long [17]. The SF-
36 is applicable to a broader range of conditions, but has
the common disadvantage of generic instruments; namely,
they are not designed to identify disease-specific domains
that may be important to establish clinical changes [18].
The HQLQ consists of the widely validated generic SF-36
with five added disease-specific subscales, but it excludes
patients with a chronic liver disease other than HCV. The
CLDQ is a short and therefore feasible questionnaire, but
is unable to discriminate between more advanced stages of
liver disease. The LDQOL addresses a variety of domains,
but is therefore very long (101 items) [10]. The LDSI 2.0
developed by Van der Plas etal. is short, straightforwar-
d(only 18 items) and focuses on symptom severity and
symptom hindrance, evaluating how patients experience
these specific symptoms during daily activities[19]. But in
this study, we intend to measure other aspects in addition
to symptoms. The translated CLDQ is also used to meas-
ure quality of life of Hepatitis B patients [20], and although
its reliability and validity have been evaluated, the cultural
gap is difficult to bridge. In addition, the instrument has
some inherent defects that make it inapplicable to LC
patients.
The above-mentioned instruments are designed for
chronic liver disease, but not for LC specifically. There is
difference between these two disease types. Another
point worth noting is that Japanese-related research has
found no statistically significant differences among dif-
ferent severity levels of liver disease [13]. However, the
LC-PROM tool differs from the scale these researchers
used, which was translated directly from English. The
LC-PROM is designed specifically for LC, and its item
pool took shape through deep interviewing and cognitive
testing of patients. Therefore, our instrument may be
accepted by respondents more easily, and it performs
better for measuring patients’ health status.
At present, liver disease questionnaires mainly focus
on “physical”, “psychological” and “limitation” dimensions.
The CLDQ also includes just six subdomains: abdominal
symptoms, fatigue, systemic symptoms, activity, emotional
function, and worry [21]. The LC-PROM contains a vital
addition—a therapeutic domain to obtain information
about treatment satisfaction, compliance and drug side ef-
fects. The satisfaction with treatment is the major out-
come index in new drug clinical trials; this additional field
provides information about effects that the trial drug has
on targeted patients’ health (such as appetite symptoms,
Table 8 Goodness of fit statistics of LC-PROM
RMSEA RMR NFI NNFI CFI IFI
PHD 0.06 0.05 0.97 0.98 0.98 0.98
PSD 0.07 0.06 0.97 0.98 0.98 0.98
SOD 0.09 0.05 0.95 0.95 0.96 0.96
TRD 0.02 0.03 0.98 0.99 1.00 1.00
Total 0.06 0.06 0.91 0.93 0.94 0.94
Table 7 Maximum Likelihood Estimation of CFA for LC-PROM (Continued)
SOD11 0.67 0.72 0.04 17.38
SOD12 0.64 0.73 0.04 16.40
TRD SAT TRD1 0.83 0.70 0.04 19.34
TRD2 0.66 0.59 0.04 15.54
TRD3 0.66 0.69 0.04 15.44
COM TRD4 0.59 0.50 0.04 11.34
TRD5 0.69 0.69 0.06 12.43
TRD6 0.56 0.42 0.04 11.00
DSE TRD7 0.79 0.87 0.05 18.92
TRD8 0.80 0.86 0.04 19.56
TRD9 0.63 0.70 0.05 14.99
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cognitive ability, independence, anxiety and depression,
and confidence) and points out the compliance charac-
teristics of the new drug among patients. These are
valuable data for clinical therapeutic drug development.
Additionally, optimal therapy can be selected according
to these measurement data. In the social domain, the
family relationship was emphasized reminding readers
of the important role of family support during patient
recovery.
During the item selection process, in addition to using
subjective methods like cognitive tests and expert dis-
cussions, we combined seven kinds of statistical methods
to refine the item pool to ensure that items retained were
maximally accurate, objective and reliable. Methods
employed to develop related scales are still limited to CTT.
The innovation of our study is to put IRT into use in
addition to CTT. IRT is able to make up for some disad-
vantages of CTT, allowing acquisition of items that reflect
potential traits of the population more accurately.
The instrument demonstrated excellent discriminant
ability among LC patients with varying courses of dis-
ease. At a basic level, physicians can judge different
stages of disease according to the results of the LC-
PROM. This will save time relative to the method of
full reliance on laboratory indicators.
In a word, the LC-PROM instrument we developed
fills a gap in patient-reported clinical outcomes of LC,
and lacks the deficiencies seen with existing liver disease
PRO tools. It also has the capacity to discriminate dis-
ease course, and to evaluate clinical effects and HRQOL
accurately; therefore, it will provide valuable data to new
drug development for LC.
However, this study still has quite a few limitations that
will be addressed and improved in further research
To begin, Cronbach’s α coefficient for the therapeutic
domain in the LC-PROM was less than 0.70, which sug-
gests that the internal coherence of this domain needs to
be improved further. As seen in the CFA results, the fac-
tor loading for item SOD3 (“I have told my worries to
my family”) is only 0.35, but in consideration of its spe-
cial meaning—support from family during illness—we
kept it in the final scale. In fact, in the item selection
phase, SOD3 was already suggested for deletion with
SOD1 (“Friends and relatives take care of my disease”),
but we maintained this item for the same reason. Besides,
there is no items about sexual function in the scale. The
participants expressed that these types of questions were a
little sensitive and that it was difficult to respond. We wor-
ried about the low response rate and bad overall reliability
and validity; therefore we did not include these informa-
tion in the scale. In order to expand the scope of use, a
scale containing this item will be generated in a revised
version.
A second limitation relates to criterion validity. The
LC-PROM instrument was designed for LC patients,
and although participants at different stages of the clin-
ical course were sampled, LC is the final stage of liver
disease progression, and patients are often too weak to
complete a lengthy scale. Introducing too many tests
leads to test fatigue and noncompliance, which increases
both survey cost and patients’ exhaustion levels; both in-
fluence survey results negatively. Therefore, we did not
conduct criterion validity analysis in this study;
Last but not the least, because of limited resources, our
samples were recruited from restricted regions and there-
fore may not be representative of all patients with LC.
Conclusions
Our study provides strong evidence for excellent reliabil-
ity and validity of a PRO instrument for LC. We do not
suggest that the LC-PROM can replace other related
questionnaires on liver disease, but it can obtain valuable
information on patients’ health conditions, evaluate clin-
ical effects, inform therapeutic method selection and new
drug development, as well as health service deployment
and clinical research.







Physical 63.68 ± 11.12 80.74 ± 3.11 28.73 <0.001
Psychological 52.26 ± 10.00 73.29 ± 2.76 39.52 <0.001
Social 42.29 ± 7.47 50.78 ± 3.81 17.01 <0.001
Therapeutic 30.77 ± 4.53 36.19 ± 2.61 16.73 <0.001
Total 189.00.24 ± 24.79 241.01 ± 6.76 39.51 <0.001
Table 10 Scores obtained using the LC-PROM instrument in varying disease courses of LC
<1 year 1 year~ 3 ~ years 5 ~ years F P
(n = 97) (n = 133) (n = 136) (n = 98)
Physical 67.62 ± 9.70 66.23 ± 10.65 62.15 ± 10.25 58.46 ± 11.87 15.83 <0.001
Psychological 53.82 ± 9.38 53.29 ± 10.59 51.98 ± 9.17 49.70 ± 10.49 3.49 0.016
Social 42.40 ± 6.52 43.41 ± 7.69 41.22 ± 7.42 42.13 ± 7.99 1.95 0.120
Therapeutic 32.07 ± 3.75 31.20 ± 4.81 30.32 ± 4.25 29.50 ± 4.83 6.32 <0.001
Total 195.92 ± 21.53 194.13 ± 25.10 185.67 ± 21.69 179.80 ± 27.91 10.32 <0.001
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Appendix 1
Table 11 Formation of LC-PROM item pool of 72
Item Item
PHD1. Did you feel abdominal distension? PSD8. Did you feel angry easier than usual?
PHD2. Did you have diarrhea? PSD9. Were you more indifference to things than ever?
PHD3. Did you feel fatigue often? PSD10. Did you worry about that your liver disease would infect your family?
PHD4. Did you have ascites? PSD11. Did you feel vague about your future?
PHD5. Did you feel bellyache often? PSD12. Did you think other people would live better if you died?
PHD6. Did you have pain in your liver area? PSD13. Did you lose interests in what interested you before?
PHD7. Did you have melena? PSD14 I thought I didn’t need any treatments because I wouldn’t be cured
PHD8. Did you have constipation? PSD15. I didn’t have any hope about my future
PHD9. Did you have oliguria or no urine? PSD16. Did you feel unuseful about yourself
PHD10. Did you have haematemesis? PSD17. I was pessimistic and there was nothing to make me happy
PHD11. Did you vomit? PSD18. Were you worried about that your liver cirrhosis would cause more
serious disease (like cancer)?
PHD12. Were you pale in skin and mucosa? PSD19. Did you feel anxious about your disease outcome?
PHD13. Did your skin turn yellow? PSD20. Did you have determination to fight with the disease?
PHD14. Did you look dark and dull? SOD1. Did your relatives and friends care about your disease?
PHD15. Did you feel dry in your eyes? SOD2. Did your family take care of your living actively?
PHD16. Did you feel itchy in skin? SOD3. Did your family comfort you?
PHD17. Did you have symptoms of bleeding gums or nasal
bleeding?
SOD4. Did you tell your worries to your family?
PHD18. Did you feel loss of appetite? SOD5. Did you feel uncomfortable about friends’ strange eyes or attitude after you
were ill?
PHD19. Did you have abnormal tastes (bitter, sweet, or stick) SOD6. Did you feel someone avoided you deliberately?
PHD20. Did you feel sleepy in daytime? SOD7. Did you avoid social occasions or activities because of disease (like parties)?
PHD21. Did you feel dizzy? SOD8. Did you give up your hobbies before (like dancing, playing cards)
PHD22. Were you losing weight? SOD9. Were you lack of initiative in social life?
PHD23. Did you feel breath hard? SOD10. Did the disease affect your interpersonal relationships?
PHD24. Did you have edema in your legs? SOD11. Did you continue to go to work at your original workplace?
PHD25. Did you feel mental decline? SOD12. Were you worried about the disease would affect your work or
promotion?
PHD26. Did you feel forgetful? TRD1. Were you satisfied with current treatments?
PHD27. Could you do shopping as usual (like buying vegetables
or daily necessities)?
TRD2. Were you satisfied with the medical services?
PHD28. Can you do simple housework (like cooking, dumping) TRD3. Were you satisfied with the health care costs?
PHD29. Can you do some simple outdoor activities (like
walking)?
TRD4. Can you follow the doctor’s advices to give up bad living habits ?
PSD1. Did you feel anxious easier than usual? TRD5. Can you go to visit doctors regularly?
PSD2. Did you feel upset or fear easily? TRD6. Can you take medicine following the doctor’s advice (in hospital or
at home)?
PSD3. Were you difficult to fall asleep, dreaming and waking
up early?
TRD7. Were you tired of taking medicine often?
PSD4. Did you feel restless and have to activate? TRD8. Did you feel annoyed about drawing blood and taking B ultrasonic
examination?
PSD5. Did you feel in a blue mood? TRD9. Did you know side effects of pharmaceutical drugs?
PSD6. Did you feel like crying? TRD10. Were you worried about side effects of drugs?
PSD7. Did you often feel lonely? TRD11. Did treatments increase your life confidence?
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Appendix 2
Table 12 Final version of LC-PROM
A. Physical Domain




1. I felt abdominal distension 0 1 2 3 4
2. I felt fatigue 0 1 2 3 4
3. I had pain in right upper quadrant 0 1 2 3 4
4. I had melena 0 1 2 3 4
5. I had haematemesis 0 1 2 3 4
6. I vomited or nauseated 0 1 2 3 4
7. My face looked dark and dull 0 1 2 3 4
8. I felt itchy in skin 0 1 2 3 4
9. I felt loss of appetite 0 1 2 3 4
10. I had abnormal tastes (bitter, sweet, or stick) 0 1 2 3 4
11. I felt sleepy in daytime 0 1 2 3 4
12. I was losing weight 0 1 2 3 4
13. I had edema in my legs 0 1 2 3 4
14. I felt forgetful 0 1 2 3 4
15. I was slow in reacting 0 1 2 3 4
Unable Occasionally About half
of the time
Often Always
16. I can do shopping as usual (like buying vegetables or
daily necessities)
0 1 2 3 4
17. I can do simple housework (like cooking, dumping) 0 1 2 3 4
18. I can do some simple outdoor activities (like walking) 0 1 2 3 4
B. Psychological Domain




1. I felt anxious easier than usual 0 1 2 3 4
2. I felt upset or fear easily 0 1 2 3 4
3. I was annoyed at abdominal pain and indigestion 0 1 2 3 4
4. I had poor sleep at night 0 1 2 3 4
5. I felt restless and had to activate 0 1 2 3 4
6. I felt in a blue mood 0 1 2 3 4
7. I felt like crying 0 1 2 3 4
8. I felt angry easier than usual 0 1 2 3 4
9. I was worried about that my liver disease would infect my family 0 1 2 3 4
10. I felt vague about my future 0 1 2 3 4
11. I lost interests in what interested me before 0 1 2 3 4
12. I didn’t have any hope about my future 0 1 2 3 4
13. I felt unuseful about myself 0 1 2 3 4
14. I was pessimistic and there was nothing to make me happy 0 1 2 3 4
15. I was worried about that my liver cirrhosis would cause more
serious disease (like cancer)
0 1 2 3 4
16. I felt anxious about my disease outcome 0 1 2 3 4
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Table 12 Final version of LC-PROM (Continued)
C. Social Domain




1. My relatives and friends cared about my disease 0 1 2 3 4
2. My family comforted me 0 1 2 3 4
3. I told my worries to my family 0 1 2 3 4




4. I felt uncomfortable about friends’ strange eyes or attitude
after I was ill
0 1 2 3 4
5. I felt someone avoided me deliberately 0 1 2 3 4
6. I avoided social occasions or activities because of disease
(like parties)
0 1 2 3 4
7. I gave up my hobbies before (like dancing, playing chess) 0 1 2 3 4
8. I was lack of initiative in social life 0 1 2 3 4
9. The disease affected my interpersonal relationships 0 1 2 3 4
10. It was easy to relax being with others 0 1 2 3 4
11. I continued to go to work at my original workplace 0 1 2 3 4
12. I was worried about that the disease would affect my work,
promotion or work force
0 1 2 3 4
D. Therapeutic Domain
Very dissatisfied Dissatisfied General Satisfied Very satisfied
1. I was satisfied with current treatments 0 1 2 3 4
2. I was satisfied with the medical services 0 1 2 3 4
3. I was satisfied with the health care costs 0 1 2 3 4
Unable Occasionally About half
of the time
Often Always
4. I can follow the doctor’s advice to give up bad living habits 0 1 2 3 4
5. I can go to visit doctors regularly 0 1 2 3 4
6. I can take medicine following the doctor’s advice (in hospital or
at home)
0 1 2 3 4




7. I was tired of taking medicine often 0 1 2 3 4
8. I felt annoyed about drawing blood and taking B ultrasonic
examination
0 1 2 3 4
9. I was worried about side effects of drugs 0 1 2 3 4
Zhang et al. Health and Quality of Life Outcomes  (2016) 14:75 Page 15 of 16
Received: 19 November 2015 Accepted: 3 May 2016
References
1. Sprangers MA, Aaronson NK. The role of health care providers and significant
others in evaluating the quality of life of patients with chronic disease: a review.
J Clin Epidemiol. 1992;45(7):743–60.
2. U.S. Department of Health and Human Service,FDA,Center for Drug Evaluation
and Research,Center for Biologics Evaluation and Research,Center for Devices
and Radiological Health. Guidance for Industry-Patient Reported Outcome
Measures: Use in Medical Product Development to Support Labeling Claims
[EB/OL]. (2009-03-07) [2015-05-10]. http://hqlo.biomedcentral.com/articles/10.
1186/1477-7525-4-79.
3. Gorecki C, Brown JM, Cano S, et al. Development and validation of a
new patient-reported outcome measure for patients with pressure ulcers:
the PU-QOL instrument. Health Qual Life Outcomes. 2013;11:95. http://www.
hqlo.com/content/11/1/95.
4. Greenhalgh J. The applications of PROs in clinical practice: what are they,
do they work, and why? Qual Life Res. 2009;18:115–23.
5. Velikova G, Booth L, Smith A, Brown P, Lynch P, Brown J. Measuring quality
of life in routine oncology practice improves communication and patient
well-being: A randomised controlled trial. J Clin Oncol. 2004;22:714–24.
6. Yanbo Z. Latent Variable Analysis[M]. Beijing: Higher Education Press;
2009. p. 1–5.
7. Hambleton RK, Hariharan S. Item Response Theory: Principles and
Applications. Boston: Kluwer Nijhoff Publishing; 1985. p. 1–9.
8. Dodd BG, De ARJ, Koch WR. Computerized adaptive testing with
Polytomous items. Appl Psychol Meas. 1995;19(1):5–22.
9. Seock-Ho K, Cohen AS. A comparison of linking and concurrent calibration
under the graded response model. Appl Psychol Meas. 2002;26(1):25–41.
10. Gutteling JJ, De Man RA, Busschbach JJ, Darlington AS. Overview of research on
health-related quality of life in patients with chronic liver disease. Neth J Med.
2007;65:227–34.
11. Bao Z, Qiu D, Ma X. Evaluation of QOL Scale of Chronic Liver Disease[J].
Chinese. Hepatology. 2008;13(4):332–3.
12. Haimiao Z, Jingping Z, Yongai Z. Research on the Influencing Factors of the
Quality of Life in Hospitalized Patients with Hepatic Cirrhosis [J]. J Med Res.
2013;42(10):110–2.
13. Atsushi Tanaka, Kentaro Kikuchi, Ryo Miura etal. Validation of the Japanese
version of the Chronic Liver Disease Questionnaire (CLDQ) for the assessment
of health-related quality of life in patients with chronic viral hepatitis[J].
doi:10.1111/hepr.12524.
14. Bajaj JS, Thacker LR, Wade JB, et al. PROMIS computerised adaptive tests are
dynamic instruments to measure health-related quality of life in patients
with cirrhosis. Aliment Pharmacol Ther. 2011;34(9):1123–32.
15. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for
clinicians and epidemiologists. J R Coll Gen Pract. 1985;35(273):185–8.
16. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A
quantitative approach to perceived health status: a validation study. J
Epidemiol Community Health. 1980;34:281–6.
17. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile:
development and final revision of a health status measure. Med Care.
1981;19(8):787–805.
18. Jenney ME, Campbell S. Measuring quality of life. Arch Dis Child.
1997;77(4):347–50.
19. Simone M, Simone M, Der Plas V, Hansen BE, De Boer JB, et al. The Liver
Disease Symptom Index 2.0; Validation of a disease-specific questionnaire.
Qual Life Res. 2004;13:1469–81.
20. Chuanghong W, Qiwen D, Xiaoshu J, et al. Preliminary Use of the CLDQ in
Chronic Hepatitis B Patients [J]. Chin J Clin Psychol. 2003;11:60–2.
21. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific
questionnaire to measure health related quality of life in patients with
chronic liver disease. Gut. 1999;45:295–300.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhang et al. Health and Quality of Life Outcomes  (2016) 14:75 Page 16 of 16
